Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 11, 2021
Share
Genovate Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 118.18 million compared to TWD 121.4 million a year ago. Net loss was TWD 7.53 million compared to net income of TWD 14.32 million a year ago. Basic loss per share from continuing operations was TWD 0.07 compared to basic earnings per share from continuing operations of TWD 0.13 a year ago. Diluted loss per share from continuing operations was TWD 0.07 compared to diluted earnings per share from continuing operations of TWD 0.13 a year ago.
For the nine months, sales was TWD 322.01 million compared to TWD 381.27 million a year ago. Net loss was TWD 1.78 million compared to net income of TWD 46.99 million a year ago. Basic loss per share from continuing operations was TWD 0.02 compared to basic earnings per share from continuing operations of TWD 0.44 a year ago. Diluted loss per share from continuing operations was TWD 0.02 compared to diluted earnings per share from continuing operations of TWD 0.43 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
GENOVATE BIOTECHNOLOGY CO., LTD. 